HDAC6 and neoplasm: Furthermore, as selective HDAC6 inhibition increases the immunogenicity of tumor cells, effective antigen presentation, and immune cell functions and reduces immunosuppression in the TME, HDAC6 inhibitors could potentially improve the antitumor immune response in the context of therapy with IC inhibitors in metastatic CRC tumors.